Generic Drugs – Decreasing Costs and Room for Increased Number of Kidney Transplantations

1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999; 341(23): 1725-1730.10.1056/NEJM199912023412303Search in Google Scholar

2. Barnieh L, Yilmaz S, McLaughlin K, et al. The cost of kidney transplant over time. Prog Transplant. 2014; 24(3): 257-62.10.7182/pit2014710Search in Google Scholar

3. James A, Mannon RB. The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable? Curr Transplant Rep. 2015; 2(2): 113-121.10.1007/s40472-015-0052-ySearch in Google Scholar

4. Allard J, Fortin MC. Is it ethical to prescribe generic immunosuppressive drugs to renal transplant patients? Can J Kidney Health Dis. 2014; 1: 23.Search in Google Scholar

5. Generic Drugs. Center for Drug evaluation and Research, U.S. Food and Drug Administration. [Cited 2015 July 13rd] Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ucm127615.pdf.Search in Google Scholar

6. Generic Drugs. World Health Organisation. [Cited 2015 July 13rd] Available from: http://www.who.int/trade/glossary/story034/en/.Search in Google Scholar

7. Generic Drugs. The Free Dictionary. [Cited 2015 July 13rd] Available from: http://medicaldictionary.thefreedictionary.com/Drugs%2c+generic.Search in Google Scholar

8. EFPIA. The Pharmaceutical Industry in Figures, key data 2014. [Cited 2015 July 13rd] Available from: http://www.efpia.eu/uploads/Figures_2014_Final.pdf.Search in Google Scholar

9. Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther. 2003; (11): 2875-90.10.1016/S0149-2918(03)80340-5Search in Google Scholar

10. Gondos A, Döhler B, Brenner H, Opelz G. Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation. 2013; 95(2): 267-74.10.1097/TP.0b013e3182708ea823060279Search in Google Scholar

11. Roodnat JI, Hilbrands LB, Hené RJ, et al. 15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation. Transplantation. 2014; 98(1): 47-53.10.1097/01.TP.0000442774.46133.7124521775Search in Google Scholar

12. Gaynor JJ, Ciancio G, Guerra G, et al. Graft failure due to noncompliance among 628 kidney transplant recipients with long-term follow-up: a single-center observational study. Transplantation. 2014; 97(9): 925-33.10.1097/01.TP.0000438199.76531.4a24445926Search in Google Scholar

13. Couzi L, Moulin B, Morin MP, et al. Factors predictive of medication nonadherence after renal transplantation: a French observational study. Transplantation. 2013; 95(2): 326-32.10.1097/TP.0b013e318271d7c123149477Search in Google Scholar

14. Tamargo J, Le Heuzey JY, Mabo P. Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. Eur J Clin Pharmacol. 2015; 71(5): 549-567.10.1007/s00228-015-1832-0441268825870032Search in Google Scholar

15. Verbeeck RK, Musuamba FT. The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action. J Pharm Pharm Sci. 2012; 15(3): 376-88.10.18433/J3VC8JSearch in Google Scholar

16. Lionberger R, Jiang W, Huang SM, Geba G: Confidence in generic drug substitution. Clin Pharmacol Ther. 2013; 94: 438-440.10.1038/clpt.2013.10424048239Search in Google Scholar

17. van Gelder T, Gabardi S. Methods, strengths, weaknesses, and limitations of bioequivalence tests with special regard to immunosuppressive drugs. Transpl Int. 2013; 26: 771-7.10.1111/tri.1207423441971Search in Google Scholar

18. Waiser J, Slowinski T, Brinker-Paschke A, et al. Impact of the variability of cyclosporin A trough levels on long-term renal allograft function. Nephrol Dial Transplant. 2002; 17(7): 1310-7.10.1093/ndt/17.7.131012105257Search in Google Scholar

19. Spasovski G, Masin-Spasovska J, Ivanovski N. Do we have the same clinical results with Neoral and Equoral treatment in kidney transplant recipients? A pilot study. Transpl Int. 2008; 21(4): 392-4.10.1111/j.1432-2277.2007.00612.x18069921Search in Google Scholar

20. Borra LC, Roodnat JI, Kal JA, et al. High withinpatient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant. 2010; 25(8): 2757-63.10.1093/ndt/gfq09620190242Search in Google Scholar

21. Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012; 12(2): 388-99.10.1111/j.1600-6143.2011.03840.x22081892Search in Google Scholar

22. Vítko S, Ferkl M. Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trial. Kidney Int Suppl. 2010; (115): S12-6.10.1038/ki.2009.50620150905Search in Google Scholar

23. Alloway RR, Sadaka B, Trofe-Clark J, et al. A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant Recipients. Am J Transplant. 2012; 12(10): 2825-2831.10.1111/j.1600-6143.2012.04174.x347202022759200Search in Google Scholar

24. Melilli E, Crespo E, Sandoval D, et al. De novo use of a generic formulation of tacrolimus versus reference tacrolimus in kidney transplantation: evaluation of the clinical results, histology in protocol biopsies, and immunological monitoring. Transpl Int. 2015; 28(11): 1283-90.10.1111/tri.1262626088437Search in Google Scholar

25. Molnar AO, Fergusson D, Tsampalieros AK, et al. Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis. BMJ. 2015; 350: h3163.10.1136/bmj.h3163447631726101226Search in Google Scholar

26. Johnston A. Equivalence and interchangeability of narrow therapeutic index drugs in organ transplantation. Eur J Hosp Pharm Sci Pract. 2013; 20(5): 302-307.10.1136/ejhpharm-2012-000258378663024089632Search in Google Scholar

27. Harrison JJ, Schiff JR, Coursol CJ, et al. Generic immunosuppression in solid organ transplantation: a Canadian perspective. Transplantation. 2012; 93: 657-665.10.1097/TP.0b013e3182445e9d22267158Search in Google Scholar

28. Alloway RR, Isaacs R, Lake K, et al. Report of the American Society of Transplantation conference on immunosuppressive drugs and the Use of generic immunosuppressants. Am J Transplant. 2003; 3: 1211-1215.10.1046/j.1600-6143.2003.00212.x14510694Search in Google Scholar

29. Gordon EJ, Prohaska TR, Sehgal AR. The financial impact of immunosuppressant expenses on new kidney transplant recipients. Clin Transplant. 2008; 22: 738-748.10.1111/j.1399-0012.2008.00869.x259249418673373Search in Google Scholar

30. van Gelder T. European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs. Transpl Int. 2011; 24: 1135-1141.10.1111/j.1432-2277.2011.01378.x22032583Search in Google Scholar

31. Minogue B. The two fundamental duties of the physician. Acad Med. 2000; 75: 431-442.10.1097/00001888-200005000-0000910824765Search in Google Scholar

32. Maynard A. Health care rationing: doing it better in public and private health care systems. J Health Polit Policy Law. 2013; 38: 1103-1127.10.1215/03616878-237315723974472Search in Google Scholar

33. Devaney A, Lee M. The use of generic immunosuppression for transplant patients: a UK perspective. Eur J Hosp Pharm. 2013; 20: 272-274. 10.1136/ejhpharm-2013-000336Search in Google Scholar